Hochschulschrift
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Berlin, Humboldt Universität zu Berlin, Dissertation, 2016
- Keyword
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Berlin
- (who)
-
Lebenswissenschaftliche Fakultät
- (when)
-
2016
- Creator
- Contributor
-
Ehrenhofer-Murray, Ann
Haendler, Bernhard
Ocker, Matthias
- URN
-
urn:nbn:de:kobv:11-100243276
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:46 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Klingbeil, Olaf
- Ehrenhofer-Murray, Ann
- Haendler, Bernhard
- Ocker, Matthias
- Lebenswissenschaftliche Fakultät
Time of origin
- 2016
Other Objects (12)
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Frequency and clinicopathologic correlates of KRAS amplification in Non-small cell lung carcinoma
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Inhibition of LSD1 in non-small cell lung cancer - in vitro and in vivo
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Frequency and clinicopathologic correlates of KRAS amplification in Non-small cell lung carcinoma
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Inhibition of LSD1 in non-small cell lung cancer - in vitro and in vivo
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Frequency and clinicopathologic correlates of KRAS amplification in Non-small cell lung carcinoma
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Inhibition of LSD1 in non-small cell lung cancer - in vitro and in vivo
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung